---
document_datetime: 2025-10-21 10:26:48
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/bimervax-epar-all-authorised-presentations_en.pdf
document_name: bimervax-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.6409958
conversion_datetime: 2025-12-31 04:48:34.299317
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented)        | Strength   | Pharmaceutical         | Route of          | Immediate    | Content         | Pack size                       |
|------------------|-------------------|------------|------------------------|-------------------|--------------|-----------------|---------------------------------|
|                  | name              |            | Form                   | Administration    | Packaging    | (concentration) |                                 |
| EU/1/22/1709/001 | BIMERVAX          | --¹        | Emulsion for injection | Intramuscular use | vial (glass) | 5 ml (10 doses) | 10 multidose vials (100 doses)  |
| EU/1/22/1709/002 | BIMERVAX          | --¹        | Emulsion for injection | Intramuscular use | vial (glass) | 0.5 ml (1 dose) | 5 single dose vials (5 doses)   |
| EU/1/22/1709/003 | BIMERVAX          | --¹        | Emulsion for injection | Intramuscular use | vial (glass) | 0.5 ml (1 dose) | 10 single dose vials (10 doses) |
| EU/1/22/1709/004 | BIMERVAX          | --¹        | Emulsion for injection | Intramuscular use | vial (glass) | 0.5 ml (1 dose) | 20 single dose vials (20 doses) |
| EU/1/22/1709/005 | BIMERVAX XBB.1.16 | --2        | Emulsion for injection | Intramuscular use | vial (glass) | 0.5 ml (1 dose) | 5 single dose vials (5 doses)   |
| EU/1/22/1709/006 | BIMERVAX XBB.1.16 | --2        | Emulsion for injection | Intramuscular use | vial (glass) | 0.5 ml (1 dose) | 10 single dose vials (10 doses) |
| EU/1/22/1709/007 | BIMERVAX XBB.1.16 | --2        | Emulsion for injection | Intramuscular use | vial (glass) | 0.5 ml (1 dose) | 20 single dose vials (20 doses) |
| EU/1/22/1709/008 | BIMERVAX LP.8.1   | --³        | Emulsion for injection | Intramuscular use | vial (glass) | 0.5 ml (1 dose) | 10 single dose vials (10 doses) |
| EU/1/22/1709/009 | BIMERVAX LP.8.1   | --³        | Emulsion for injection | Intramuscular use | vial (glass) | 0.5 ml (1 dose) | 20 single dose vials (20 doses) |
| EU/1/22/1709/010 | BIMERVAX LP.8.1   | --³        | Emulsion for injection | Intramuscular use | vial (glass) | 0.5 ml (1 dose) | 1 single dose vial (1 dose)     |

--¹:

One dose (0.5 mL) contains:

40 micrograms of selvacovatein adjuvanted with SQBA (EU/1/22/1709/001-004).

Selvacovatein is a SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351 and B.1.1.7 strains) produced by recombinant DNA technology using a plasmid expression vector in a CHO cell line.

SQBA adjuvant containing per 0.5 mL dose: squalene (9.75 mg), polysorbate 80 (1.18 mg), sorbitan trioleate (1.18 mg), sodium citrate (0.66 mg), citric acid (0.04 mg) and water for injections.

-- 2 :

One dose (0.5 mL) contains:

40 micrograms of damlecovatein adjuvanted with SQBA (EU/1/22/1709/005-007).

Damlecovatein is a SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion homodimer (Omicron XBB.1.16 - XBB.1.16 strain) produced by recombinant DNA technology using a plasmid expression vector in a CHO cell line.

SQBA adjuvant containing per 0.5 mL dose: squalene (9.75 mg), polysorbate 80 (1.18 mg), sorbitan trioleate (1.18 mg), sodium citrate (0.66 mg), citric acid (0.04 mg) and water for injections.

--³:

One dose (0.5 mL) contains:

<div style=\"page-break-after: always\"></div>

40 micrograms of SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion homodimer* (Omicron LP.8.1-LP.8.1 strain) adjuvanted with SQBA ( EU/1/22/1709/008-010) .

*Produced by recombinant DNA technology using a plasmid expression vector in a CHO cell line.

SQBA adjuvant containing per 0.5 mL dose: squalene (9.75 mg), polysorbate 80 (1.18 mg), sorbitan trioleate (1.18 mg), sodium citrate (0.66 mg), citric acid (0.04 mg) and water for injections.